AngioDynamics, Inc.
NASDAQ:ANGOMedical - Instruments & Supplies
+$0.20 today
- Market cap
- $476.06M
- Beta
- 0.36
- P/E (TTM)
- -15.8
- EPS (TTM)
- -$0.75
Volume 0.32M
Average 0.40M
ANGO Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
AngioDynamics, Inc.NASDAQ: ANGO
Total Equity · Q3 FY2026 · quarter ended Feb 2026
Total equity falls 6.7% from a year ago
Total equity stood at $173.36M at the end of Q3 FY2026, down 6.7% from a year earlier and down 1.7% from the prior quarter. Over 3 fiscal years it compounded at -24.5% a year.
Context
- Total equity amounted to 66.5% of total assets at the end of Q3 FY2026, up 1.4 pp from a year earlier.
- Total equity increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -6.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 182.97M USD
- Year-over-year change
- -11.0%
- 4-year CAGR
- -19.7%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-05-31 | 182.97M | -11.0% |
| FY2024 | 2024-05-31 | 205.59M | -45.7% |
| FY2023 | 2023-05-31 | 378.3M | -10.9% |
| FY2022 | 2022-05-31 | 424.49M | -3.4% |
| FY2021 | 2021-05-31 | 439.46M | — |
Total Equity vs competitors
How ANGO compares with its peers on the latest reported figures
- ANGO's Feb 2026 total equity of $173.36M is the lowest of the 9 companies compared; the peer median is $1.64B.
- Its year-over-year change of -6.7% is the 7th highest of 9, against a peer median of +7.6%.
- Total equity amounts to 66.5% of total assets for ANGO, versus a peer median of 48.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $25.17B | +11.1% | +11.7% | 55.7% | |
| Sep 2026 | $24.68B | -2.8% | -1.5% | 48.6% | |
| Jun 2026 | $2.9B | -31.5% | -8.1% | 42.8% | |
| Sep 2026 | $1.74B | +14.1% | +11.5% | — | |
| Jun 2026 | $1.53B | +18.3% | +12.6% | 77.5% | |
| Mar 2026 | $1.04B | -31.6% | -16.7% | 29.1% | |
| Mar 2026 | $1.02B | +4.1% | +11.5% | 44.0% | |
| Mar 2026 | $406.62M | +17.0% | +13.6% | 64.6% | |
| Feb 2026 | $173.36M | -6.7% | -24.5% | 66.5% | |
| Peer median (excluding ANGO) | $1.64B | +7.6% | +11.5% | 48.6% | |
Competitors are the stored peer set for ANGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 May 2021 | FY2022 May 2022 | FY2023 May 2023 | FY2024 May 2024 | FY2025 May 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 48.16M | 28.83M | 44.62M | 76.06M | 55.89M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 37.32M | 56.5M | 52.83M | 50.01M | 43.14M |
| Inventory | 48.61M | 51.39M | 55.33M | 60.62M | 62.01M |
| Other Current Assets | 1.76M | 2.2M | 7.26M | 2.58M | 3.07M |
| Total Current Assets | 140.88M | 143.35M | 163.54M | 193.25M | 168.32M |
| Property, Plant & Equipment (Net) | 37.07M | 45.01M | 44.38M | 35.67M | 32.3M |
| Goodwill | 201.32M | 201.06M | 159.24M | 0 | 0 |
| Intangible Assets | 168.98M | 152.38M | 111.14M | 77.38M | 69.12M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 13.19M | 10.96M | 54.33M | 11.37M | 10.4M |
| Total Non-current Assets | 420.56M | 409.41M | 369.1M | 124.42M | 111.82M |
| Total Assets | 561.44M | 552.75M | 532.64M | 317.67M | 280.14M |
| Account Payables | 19.63M | 28.05M | 40.45M | 37.75M | 33.29M |
| Short-term Debt | 0 | 8.78M | 14.76M | 4.73M | 400K |
| Tax Payables | 631K | 750K | 480K | 520K | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.04M | 2.71M | 2.26M | 9.06M | 5.52M |
| Total Current Liabilities | 57.58M | 74.32M | 83.83M | 91.16M | 76.2M |
| Long-term Debt | 20M | 25M | 49.82M | 0 | 5.8M |
| Deferred Tax Liabilities | 19.96M | 16.04M | 12.81M | 4.85M | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 24.44M | 12.9M | 7.89M | 16.08M | 13.07M |
| Total Non-current Liabilities | 64.4M | 53.94M | 70.52M | 20.93M | 20.98M |
| Total Liabilities | 121.98M | 128.26M | 154.34M | 112.09M | 97.17M |
| Common Stock | 377K | 380K | 382K | 385K | 385K |
| Retained Earnings | (131.87M) | (158.41M) | (210.86M) | (395.2M) | (429.2M) |
| Accumulated OCI | 3.15M | 1.36M | (4.72M) | (4.37M) | (2.02M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 439.46M | 424.49M | 378.3M | 205.59M | 182.97M |
| Total Debt | 20M | 33.78M | 64.58M | 4.73M | 10.15M |
| Net Debt | (28.16M) | 4.96M | 19.96M | (71.33M) | (45.75M) |
AngioDynamics, Inc.
NASDAQ:ANGO
Intrinsic Alpha fair value
Locked
Current Price
$11.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.